Tirzepatide Dosage Chart: Full Escalation Schedule for Mounjaro and Zepbound

Quick Answer

Tirzepatide starts at 2.5 mg weekly and escalates every 4 weeks to a maximum of 15 mg weekly. The escalation schedule exists to minimize GI side effects — going too fast dramatically increases nausea and vomiting. Most patients find their optimal dose between 10–15 mg. The schedule is identical for both Mounjaro (diabetes) and Zepbound (obesity).

Standard Tirzepatide Dosage Chart

Week	Dose	Purpose
Weeks 1–4	2.5 mg	Starting dose — tolerance building
Weeks 5–8	5 mg	First escalation
Weeks 9–12	7.5 mg	Second escalation
Weeks 13–16	10 mg	Third escalation
Weeks 17–20	12.5 mg	Fourth escalation
Week 21+	15 mg	Maximum dose (maintenance)

Frequency: Once weekly, same day each week. Injection timing can be any time of day, with or without food.

Available dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg — each as a separate auto-injector pen for Zepbound, or a vial for the LillyDirect self-pay format.

Can You Stay at a Lower Dose?

Yes — the maximum 15 mg dose is a ceiling, not a requirement. Many patients achieve their weight loss or diabetes goals at 5, 7.5, or 10 mg and elect to remain at that dose rather than escalating further.

The trade-off: higher doses produce greater weight loss on average (SURMOUNT data shows approximately 16% loss at 5 mg vs. 22% at 15 mg), but also higher rates of GI side effects. Finding the "optimal" dose is individual — the dose that produces acceptable side effects while achieving the patient's goals.

Slowing Down the Escalation Schedule

The standard 4-week escalation is a guideline, not a hard rule. Prescribers commonly modify it for patients experiencing significant side effects:

Extended escalation: Staying at a dose for 8 weeks instead of 4 before increasing. This gives the GI system more time to adapt and often produces much better tolerability.

Retreating to a lower dose: If a dose increase causes intolerable side effects, most prescribers support stepping back down to the previous dose for 4–8 weeks before trying again.

Pausing escalation: Some patients find their ideal dose mid-schedule and simply don't escalate further. There is no requirement to reach 15 mg.

The most important principle: slower escalation is almost always better than faster. The data on weight loss outcomes shows only modest differences between doses for most patients, while the tolerability difference is significant.

Tirzepatide Dosing for Type 2 Diabetes (Mounjaro)

For Mounjaro in type 2 diabetes, the dosage schedule is identical (2.5 mg → 15 mg weekly escalation), but the therapeutic target differs:

A1c reduction: All doses produce meaningful A1c reductions. The maximum effect is generally reached at 10–15 mg.
Insulin adjustment: Patients on concurrent insulin typically require dose reductions as tirzepatide improves glycemic control. This must be managed with the prescribing clinician.
Concurrent metformin: Safe to use together; no dose adjustment required for either medication.

What Happens if You Miss a Dose?

Within 4 days of the missed dose: Take it as soon as remembered, then resume your regular weekly schedule.

More than 4 days after the missed dose: Skip the missed dose and resume on your next scheduled day.

Never take two doses in the same week to make up for a missed dose. Double-dosing significantly increases GI side effect risk.

Tirzepatide Self-Pay Vial Dosing

Patients using LillyDirect self-pay vials (rather than the auto-injector pens) draw the dose themselves with a syringe. The same dose strengths apply, but administration requires careful measurement:

Use a 1 mL insulin syringe with a 29–31 gauge needle
Draw exactly the prescribed volume from the vial
Inject subcutaneously (into fat tissue of the abdomen, thigh, or upper arm)
Rotate injection sites each week

Dosing errors are more likely with vials than pens. Patients switching from pen to vial format should receive training from their prescriber or pharmacist.

Stopping Tirzepatide: What Happens to Your Dose

If treatment is interrupted (due to cost, supply, or choice) and then restarted, prescribers typically restart at a lower dose rather than continuing at the dose where treatment stopped. The GI system readapts to tirzepatide after a break.

General guideline: if the break was more than 4 weeks, restart at 2.5 mg and re-escalate. For shorter breaks (1–4 weeks), the prescriber may restart at the previous dose or one dose level lower, based on patient tolerance.

Bottom Line

The tirzepatide escalation schedule — 2.5 mg to 15 mg over 20 weeks — is designed to minimize GI side effects while building to maximum efficacy. Slowing the escalation or staying at a comfortable intermediate dose is clinically appropriate and often preferable to pushing to the maximum. The schedule is the same for Mounjaro and Zepbound; the target metric (A1c vs. weight) differs.